Category Archives: Hormone Replacement Therapy

Hormone replacement therapy may slash the odds of menopausal women getting diabetes, research suggests.

Scientists believe the common treatment may keep blood sugar in check, therefore protecting against the development of type 2 diabetes.

A group of women who had been on HRT for a year had far lower rates of the condition than volunteers given a placebo.

Tests revealed they had improved markers of insulin sensitivity and blood glucose since they began the treatment.

The study comes amid a nationwide crisis in HRT stocks and a bombshell Oxford study that found it raised the risk of breast cancer by a third.

Around one million women in the UK turn to treatments to manage the menopause, according to the National Institute for Health and Care Excellence.

HRT, which comes in the form of pills, patches and gels, is used by the majority.

It works by replenishing levels of oestrogen and progesterone, which lower as a women approaches menopause, in turn combating symptoms such as hot flushes and night sweats.

Hot flushes raise the risk of women suffering from heart attacks or strokes later in life, according to a study from the University of Pittsburgh.

Researchers, led byDr Rebecca Thurston, used The Study of Womens Health Across the Nation (SWAN), which spanned 20 years.

It regularly assessed hot flushes, also known as hot flashes, and collected information on cardiovascular (CVD) events.

Analysis found frequent hot flashes at the beginning of the study doubled the risk of CVD events.

Persistent hot flashes over the study were linked to an 80 per cent increased risk of CVD events in the subsequent 20 years.

The results are considered strong compared to previous studies that have attempted to link hot flushes with CVD risk.

Most studies have relied on subclinical measures of CVD, which is not hard evidence of whether a patient actually went on to have a heart attack or stroke.

They have also relied upon womens recalling how many hot flushes they had years earlier, which can be biased by memory.

The study findings will be presented in September during The North American Menopause Society Annual Meeting in Chicago.

The Womens Health Initiative (WHI) is an organisation at the forefront of debating the benefits and risks of hormone therapy.

The study, led by The Ohio State University Medical Center, used data from a prior study by WHI on 1,362 women.

Cases of type 2 diabetes were 21 per cent lower in the group of women taking hormone therapy consisting of a combination of oestrogen and progestin.

The researchers looked at various markers in the womens blood which were collected at the beginning of the study and a year after taking hormone therapy.

These markers are called metabolites, and are molecules which reflect the inner workings of a persons metabolism.

Approximately 370 metabolites were recorded in the WHI study, but the researchers only looked at nine.

These nine metabolites have previously been linked with the development of type 2 diabetes, including glycine, glutamine, and a host of amino acids.

Of the nine targeted metabolites, seven were significantly decreased with the use of combination hormone therapy.

Five were significantly decreased with the oestrogen-only therapy, whichis usually only taken by women who have had their womb removed in a hysterectomy.

Women aged 70-79 benefited most from their hormone therapy, with the effects lessened in younger women.

Dr Heather Hirsch, lead author of the study, said: Interestingly, we found that the decreases were more pronounced with the use of estrogen and progestin combined than with estrogen alone.

This result parallels the findings from the WHI on the effect of hormone therapy on the incidence of type 2 diabetes.

The findings will be presented during The North American Menopause Society (NAMS) Annual Meeting in Chicago this month.

Dr Stephanie Faubion, NAMS medical director, said it is valuable for doctors to be aware of the potential risks and benefits of menopausal treatments, given the debilitating effects of diabetes and its increased incidence in the US.

While hormone therapy has some proven benefits, such as preventing weakening bones, there are potential risks, too.

Women who take HRT for more than one year have a higher risk of breast cancer than women who never use it.

An Oxford study, published in August, found HRT raised the risk of breast cancer in women aged 50 to 69 by a staggering 32 per cent if they had been using HRT for at least five years.

The danger was twice as high for patients on the treatment for a decade.

The studies come amid a nationwide shortage of HRT, in which two-thirds of HRT treatments have been hit by shortages.

They include Evorel and Elleste, the two most popular brands, which are prescribed to upwards of 100,000 women a year.

Menopausal women who endure night sweats sleep for longer but are also vulnerable to cognitive dysfunction.

Scientists at the University of Illinois at Chicago were surprised to find women who had more frequent night sweats also slept for longer.

But even more ironic, however, was the finding that these same women became more vulnerable to prefrontal cortex deficits, including decreased attention and executive function, as their sleep duration increased.

Executive function is responsible for paying attention, organising and planning, initiating tasks, regulating emotions and keeping self-control.

Total sleep time, however, was unrelated to memory performance.

Hot flushes in the day time had no effect on total sleep time.

Lead author John Bark, a PhD student on the Behavioral Neuroscience Program, said: This work presents novel insights into the influence of menopause symptoms on cognitive performance.

[It] raises the possibility that hot flash treatments could benefit cognition in these women through effects on sleep.

The study was conducted on women who had a history of breast cancer, and may only be applicable to them.

The study findings will be presented in September during The North American Menopause Society Annual Meeting in Chicago.

Read the rest here:
Hormone replacement therapy may slash the odds of menopausal women getting diabetes - Denton Daily

Christophe Hzode,1 Paul Kwo,2 Jan Sperl,3 Peggy Hwang,4 Jianmin Long,4 Rohit Talwani,4 Michael N Robertson,4 Barbara A Haber4

1Service dHpatologie, Hpital Henri-Mondor, AP-HP, Universit Paris-Est, INSERM U955, Crteil, France; 2Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA, USA; 3Department of Hepatogastroenterology, Institut Klinick a Experimentln Medicny (IKEM), Prague, Czech Republic; 4Department of Infectious Disease, Merck & Co., Inc., Kenilworth, NJ, USA

Correspondence: Christophe HzodeService dHepatologie, Hpital Henri Mondor, 51, avenue du Marchal de Lattre de Tassigny, Crteil 94010, FranceTel +33 14 981 2111Email christophe.hezode@aphp.fr

Introduction: Some direct-acting antiviral regimens for hepatitis C virus (HCV) infection pose safety or efficacy concerns if coadministered with drugs containing ethinyl estradiol. The present analysis was conducted to examine the impact of concomitant oral contraceptive pills (OCP) or hormone replacement therapy (HRT) during treatment with elbasvir (EBR)/grazoprevir (GZR) in women with HCV genotype (GT)1 or GT4 infection.Methods: This is a post hoc, integrated retrospective analysis of female participants with HCV GT1 or GT4 infection who received EBR 50mg/GZR 100mg once daily for 12weeks in phase 2/3 clinical trials. The primary end point was sustained virologic response at 12weeks after therapy completion (SVR12). For this analysis, participants were stratified according to whether they received OCP or HRT during the original treatment study.Results: A total of 1,022 women with HCV GT1 or GT4 infection were included (receiving OCP/HRT, n=81; not receiving OCP/HRT, n=941). Most participants receiving OCP/HRT were treatment-naive (79%), noncirrhotic (91.4%), and aged >35years (71.6%). SVR12 rates were similar in women receiving OCP/HRT and those not receiving OCP/HRT (95.1% vs 96.3%). SVR12 rates remained high across all subgroups within the population receiving OCP/HRT: SVR12 rates were 94.6%, 100%, and 100% in participants with GT1a, GT1b, and GT4 infection, and all women aged 1835years achieved SVR (21/21). Treatment-related adverse events occurred in 40.7% (33/81) and 30.1% (283/941) of women receiving and those not receiving OCP/HRT, respectively.Conclusion: The efficacy and safety of EBR/GZR administered for 12weeks was similar in women receiving OCP/HRT and those not on OCP/HRT. These data indicate that EBR/GZR can be safely used for the treatment of HCV GT1 or GT4 infection in women receiving concomitant OCP/HRT.

Keywords: clinical trial, ethinyl estradiol, levonorgestrel, NS5A inhibitor, NS3/4A protease inhibitor

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Originally posted here:
Elbasvir/grazoprevir in women with hepatitis C virus infection taking | IJWH - Dove Medical Press

The Medical Health Institute offers the Bio identical Hormone Replacement Therapy Miami, allowing people to redesign their health and get back their energy and vitality.

Men and women living in Miami may not have to worry a lot about their growing age. The age related complications can be delayed with the help of the Hormone Replacement Therapy Miami that The Medical Health Institute is offering now. The

Medical Health Institute specializes in HRT for men and women, allowing them to redesign their health with the advanced medical science. The anti-aging clinic is located in two places in North and South Miami, and their treatments help men and women to restore their bodies to optimal health. Besides HRT, the clinic also offers a variety of advanced medical services, which also includes addressing the problem of erectile dysfunction.

The clinic offers Bio identical Hormone Replacement Therapy Miami that could prove a holistic approach to anti-aging. The spokesperson of the clinic reveals that they try to address the whole system of a patient rather than treating just the symptoms. This holistic approach brings a long-lasting result or a permanent cure by eliminating the root cause of the problem. The doctors of the clinic focus on personalized treatment programs for each individual patient. They closely monitor each patients health and improvement throughout the treatment process. The HRT is an ideal therapy for men and women experiencing the problem of hormonal imbalance.

With the growing age, both men and women often suffer from the low level of testosterone. This hormone is essential to help maintain energy and vigor of the human body. The HRT Clinic in Miami offers Testosterone Replacement Therapy Miami that can improve the physical stamina and sex drive for one to experience the same youthful energy despite the growing age.

For all men suffering from the problem of erectile dysfunction, the clinic has an effective ED Treatment Miami. The clinic takes advantage of the latest GainWave technology in which sound acoustic waves are used that stimulate mens tissues, helping them to achieve a full erection, and which also lasts for a longer period of time. This is a tried and tested ED treatment, and numerous men have been treated in the Miami Clinic to regain their sexual strength.

The spokesperson talks about one more important treatment of their clinic, which is the IV Therapy Miami. In this therapy, one can absorb nutrients bypassing the bodys digestive system. The clinic delivers Vitamins and proteins to ones body through an intravenous system. These nutrients, thus directly reach a humans bloodstream, to help improve health conditions. The spokesperson reveals that IV therapy could be useful not only for aging people, but people with an active lifestyle can also choose it for their better health.

To know more about these cutting-edge treatments offered by the Medical Institute, one can visit the website https://hormone-replacement-miami.com.

About The Medical Health Institute

The Medical Health Institute is an HRT Clinic with 2 locations in North Miami and South Miami. As a full service anti-aging clinic, The Medical Health Institute specializes in Bio-Identical hormone replacement therapy. Not only are they treating low energy levels in men, but also erectile dysfunction and hair loss.

Media ContactCompany Name: Medical Health InstituteContact Person: Michael BertonattiEmail: Send EmailPhone: +1 (786) 401-5244City: MiamiState: FLCountry: United StatesWebsite: https://hormone-replacement-miami.com

Follow this link:
Hormone Replacement Therapy Miami Now Available for Improving Health & Overall Life - Press Release - Digital Journal

Hormone Replacement Therapy is any form of hormone therapy where in the patient, in course of medical treatment, receives hormones, either to supplement a lack of naturally occurring hormones, or to substitute other hormones for naturally occurring hormones.

Menopause, is the time in most womens lives when menstrual periods stop permanently, and the woman is no longer able to have children. Menopause typically occurs between 45 and 55 years of age. Medical professionals defined by a decrease in hormone production by the ovaries. In those who have had surgery to remove the uterus but still have ovaries, menopause generally occurs at the time of the surgery or when hormone levels fall. Following the removal of the uterus, symptoms typically occur earlier at the average of 45 years of age.

Estrogen and progesterone are female hormones that play important roles in a womans body. Falling levels cause a range of physical and emotional symptoms, including hot flushes, mood swings and vaginal dryness. The aim of hormone replacement therapy is to restore female hormone levels, allowing the body to function normally again.

Hormone Replacement TherapyMarket: Drivers and Restraints

The prime drivers of hormone replacement therapy are increased demand from regenerative medicines such as anti-aging and reproductive-cycle boosting therapy such as menopausal hormone replacement. Rising demand in other therapeutic areas such as Growth Hormone Therapy and Thyroid Hormone Therapy due to comparatively safe profile, efficiency, and cost effectiveness of these drugs is expected to positively impact market growth. Moreover, new formulations such as transdermal drugs, gels and creams that offer benefits such as ease of drug administration and impact at location are expected to increase the growth of hormone replacement therapy market during the forecast period. Advantages associated with the hormone replacement therapy such as reduction in risk incidence of osteoporosis, cardiovascular disease, and reduction of vasomotor symptoms are also expected to boost the growth of hormone replacement therapy market in the coming years.

Request to Sample of Report @https://www.futuremarketinsights.com/reports/sample/rep-gb-3871

Hormone Replacement Therapy has side effects such as fluid retention, headache, indigestion, and depression. These are anticipated to hamper the popularity of the therapeutic area. Furthermore, UK-based NICE notes that hormone replacement therapy could be associated with breast cancer risk if the drugs oestrogen and progesterone are taken in combination. Prolonged consumption of HRT drugs could also lead to increased risk of blood clots. Studies have estimated that for every 1,000 women taking HRT tablets for 7.5 years, less than two will develop a blood clot. These restraints seem quite negligible when compared with the benefits of HRT.

Hormone Replacement TherapyMarket: Segmentation

Hormone Replacement Therapy Market segmented based on product type, Application

Based on Therapy Type,

Based on Application

Based on Distribution Channel

Hormone Replacement TherapyMarket: Overview

Increasing use of HRT in menopause conditions due to safety, efficacy and cost effectiveness of the drugs are expected to boost the growth of the Global Hormone Replacement Therapy market. North America is contributing more income to the Global Hormone Replacement Therapy and Asia region is showing fastest growth rate because of having more population base in this region.

Hormone Replacement TherapyMarket: Region wise Outlook

Depending on geographic regions, Global Hormone Replacement Therapy market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa. North America is having more market for Hormone Replacement Therapy, In North America, U.S. represents the largest market because of increasing use of Hormone Replacement Therapy among patients aged 35 years and over. The availability of compounded drugs i.e. drugs in varied strengths, dosage forms, etc is a major factor, which tends to boost the revenue growth of this extremely popular treatment market. Early onset of aging coupled with rising disposable income levels are other important factors fuelling market revenue growth.

Asia region is expected to have more growth rate in upcoming years because of increasing awareness about Hormone Replacement Therapy in this region. In Asia region India, China, Japan are expected to have more growth rate for Hormone Replacement Therapy.

Request Report for TOC @https://www.futuremarketinsights.com/toc/rep-gb-3871

Hormone Replacement TherapyMarket: Key Players

Some of the key market players in Global Hormone Replacement Therapy market are Bayer AG, Pfizer, Merck & co., BioSante Pharmaceuticals and Amgen, QuatRx Pharmaceuticals, Noven Pharmaceuticals.

Read the original post:
Hormone Replacement Therapy Market Overview 2019 | Bayer AG, Pfizer, Merck & co., BioSante Pharmaceuticals and Amgen - Statsflash

Women are desperate to figure out why they dont feel good. By the time they come to see me, theyve been dismissed so many times, says Heather Hirsch, lead physician of Brigham and Womens Hospitals Menopause and Midlife clinic, set to open early next year. When we think about womens health, we talk about puberty, pregnancy and postpartum. The menopause transition is really important, and it gets no attention.

Hirsch, 37, is part of a new generation of doctors, tech developers and investors determined to change that, and aiming to replace stigma with public conversation, better medical research and more accessible training. Research for treatment of common symptoms like hot flashes, low libido, sleep disruption and weight gain is notoriously underfunded, they note, even as an estimated 38 million American women are menopausal and account for approximately 20 percent of the American work force.

The lack of medical research is coupled with a lack of clinical training, even for gynecologists.

In many family medicine, internal medicine and OB/GYN residency programs, there is perhaps an hour of instruction on menopause, at best, says Stephanie Faubion, medical director of the North American Menopause Society (NAMS) and director of the Mayo Clinic Center for Womens Health, where she co-authored the report Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents.

Anna Barbieri

Frustrated by misconceptions and shame surrounding the topic, doctors have found new ways to communicate with the women they say are deeply underserved. Hirsch has her own podcast series, Health by Heather Hirsch, with accessible and irreverent segments like Perimenopause, what the HEL! [sic]. In New York, a new telemedicine start-up called Elektra Health is recruiting doctors like Anna Barbieri and hosting frequent salon discussions with titles like Hormonal Harmony: Thriving in Perimenopause and Beyond.

Its important to provide current and valid information about symptoms and their management, and to discuss how this phase of life is so strongly related to other health factors, says Barbieri, 46, an assistant clinical professor of OB/GYN at Mount Sinai. We know, for example, that the time of menopause marks an increase in cardiovascular risk, diabetes risk and risk of dementia for women. How can we optimize this transition, and by doing so optimize other aspects of health? Menopause can vary widely from woman to woman, and were interested in how to practice patient-centered medicine based in evidence and rational treatments.

A reasonable approach, to be sure, but one hampered by myths and misunderstandings.

Among them, Hirsch says, is the fear of hormone replacement, largely stemming from media reporting on the early closure of a 2002 Womens Health Initiative study. That study, which examined one combined oral dose of estrogenand progesteronein a population of women whose average age was 63.5, was widelyandincorrectly interpreted as indicating that the hormones led to a significant increase in the risk of breast cancer and heart attacks.

WHI was an incredible research study with lots of information, but it was a skewed population of older, non-symptomatic women, Hirsch says. When the media spun the results, it made a huge impact in most peoples mind that estrogen is dangerous and harmful, and this idea is still very much ingrained into society.

Today, NAMS-trained providers say that hormone therapy, given to symptomatic women within 10 years of menopause (typically starting in their 50s), often has benefits.

Story continues

Recent studies, Hirsch notes, say that women who take estrogen and progesterone within 10 years of menopause have a tendency to live longer, die less from all causes and have less heart disease. These are results from several large clinical trials ofdifferent preparations ofhormone therapy in women who start within 10 years of their last menstrual period.

Even when women are willing to take hormones, they are often confused about the best sources, struggle to find well-informed doctors and are susceptible to marketing of unregulated, compounded hormones, Hirsch says.

The compounded hormone therapy industry is extremely profitable, as they are preying off the insecurities of patients and then providers who are otherwise uncomfortable discussing the risks and benefits of FDA-approved hormone therapy, with the risks being overestimated, she notes. There are approximately 15 million women on hormone therapy, of which about two-thirds use unregulated and one-third use FDA-approved medications. However, this number could be larger if there are women using compounded HT we cannot account for. Therein lies another risk of inadequate education and counseling: women taking unregulated HT with the idea that it is safer.

Theres confusion, too, about how to use and source supplements like Chasteberry and Vitex, which some women take for PMS and irregular periods; silymarin, which supports liver function; and melatonin and valerian, which may help with sleeplessness and anxiety.

I find that the use of supplements in the U.S. can be controversial and polarizing, similar to hormone therapy, with many sharing either the extreme view that no FDA oversight means that herbs and supplements are mostly ineffective and can be dangerous, and others believing the opposite, that anything that is natural is safer and gentler than regular medications, says Barbieri. I fall in the middle and believe we should apply regular scientific principles to both drugs, many of which have botanical origins, and herbs/supplements.

This fraught climate, investors say, is ripe for growth.

Last year, market research firm Frost & Sullivan predicted that the market for femtechtechnology products that focus on female wellness, everything from reproductive health to general wellnesswill be $50 billion by 2025.

Jill Angelo

Women control the majority of healthcare dollars spent, and are so influential in their spending power, but I was really taken by the lack of attention to womens health in the second half of life, says former Microsoft executive Jill Angelo, 46. This is a huge opportunity, and in terms of how much is capitalized or consumed, were just getting started.

In September 2016, Angelo launched the online platform Gennev, initially focused on selling hygiene products geared toward easing menopausal symptoms. With her partner Jacqueline Brandwynne, a retired Neutrogena executive, Angelo has branched out to providing services to its 16,000 registered users. It now offers $35 telemedicine appointments with NAMS-certified physicians and a $10 monthly subscription to unlimited consultations with health coaches, dietitians and nutritionists specifically trained to counsel menopausal women. Gennev currently partners with physicians in 30 states and expects to cover all 50 states and the District of Columbia by the end of 2020.

We interviewed 1,500 women, and they said, I have no idea who to go see. My doctor brushes me off, Angelo says. Were still growing our product line into dietary supplements but have also expanded to telemedicine and on-demand coaching. Theres a lot you can do from a lifestyle perspective to alleviate symptoms.

Amy Domangue

Amy Domangue, cofounder and CEO of the virtual medical care aggregator Jessie, calls Angelo a pioneer. The opportunity for virtual care for menopause and perimenopause is finally giving women a place so they know exactly where to turn. The way our healthcare system works is outdated, Domangue says. We have primary care and OB/GYN doctors, but what if instead of general doctors you have specialists uniquely trained to your gender and age? How can we segment healthcare better, so people know where to turn?

And while some women in their 50s and 60s may be wary of virtual visits, Domangue and other menopause entrepreneurs predict the approach will soon become normalized.

Alessandra Henderson

Telemedicine has been around for a very long time, so the technology itself is nothing new, but user behavior is very much a consideration. How do you onboard women in a way that feels comfortable and natural and that builds trust from the get-go? As we grow over time, and continue to get more women on to the platform, well continue to see more digitally native women join, says Alessandra Henderson, 34, the cofounder and CEO of Elektra Health, a new company set to debut telemedicine services in 2020, starting with a beta test group of 30 women in New York state.

Elektras model is to focus on building a virtual care practice with a dedicated care team of gynecologists on staff.We believe dedicated Elektra providers trained in our proprietary care protocol is the best way to deliver an optimal customer experience, real healthcare results, as well as to foster a long-term relationship over the seven-to-10-year menopause journey, says Henderson. Another focus for Henderson: fostering community and accountability.

Elektra checks in regularly with women in the first week, month and beyond on not only their health goals but also their symptoms. Well then use that information to inform their next meeting with the gynecologist. We also plan to add women to private, curated groups for support and accountability, she says. One hundred percent of women go through this. Its nothing to be ashamed about. Its a natural, universal experience. We want to give women the tools to live really well during this time.

This perspective is long overdue, says Faubion, noting that despite the fact that most menopausal women will suffer symptoms, theres not a great deal of new research. One area that does look promising: phase three trials on drugs inhibiting receptors in the hypothalamus that are linked to brain pathways responsible for hot flashes and night sweats. They block the NK3 receptors believed to be in the hot flash neural pathway, but an exact mechanism hasnt been determined, Faubion explains.

Doctors emphasize that menopause should also be assessed in terms of how it may relate to other health issues, particularly cardiovascular disease and dementia.

There is basically a disruption in brain energy metabolism during the menopausal transition linked to decline in estrogen, Barbieri says, adding that the decline can leads symptoms like insomnia, disturbed sleep, hot flashes, depression and short-term memory impairment. It is this metabolic change, as well as recognized vascular changes that occur with menopause, including the impact on the brains vascular system, that may be linked to higher risk of dementia for women.

Ideally, Barbieri says, technology will help researchers target womens symptoms more precisely.

Id love to see research that focuses more on precision medicine for menopause and the choice of intervention based on ones particular genetic makeup and individual situation. That could translate to different types of medicines, dosing or modalities, she says. Id also love to see more research devoted to non-pharmaceutical approaches, including natural and mind-body approaches.

These are exactly the possibilities inspiring entrepreneurs like Elektras Henderson.

The more women that we treat, the faster we can help identify what is and is not going to work, she says. We have a lot of independent research studies on diet, acupuncture and meditation, but we are aiming to build an incredibly rich data set to help informwith hard, science-based evidencewhat has helped treat symptoms, as well as what are best practices.

The post The Womens Health Issue Thats Finally Starting to Get Recognition appeared first on Worth.

See the original post here:
The Womens Health Issue Thats Finally Starting to Get Recognition - Yahoo Finance

The Salvation Army was caught off guard this week when pop singer Ellie Goulding nearly called off her halftime performance at the Dallas Cowboys Thanksgiving game because of her concerns that the charity that sponsors the show had an anti-LGBTQ bias.

But it wasnt the first time the evangelical Christian organizations North Texas leaders have heard those concerns, and the Salvation Army ultimately set Gouldings worries to rest and announced the show would go on as planned.

Maj. Jon Rich, one of the Salvation Armys area commanders, and Blake Fetterman, executive director of the Salvation Armys Carr P. Collins Social Service Center, spoke with The Dallas Morning News about what went on behind the scenes after Goulding voiced her concerns and about the services they provide to LGBTQ people in need.

When Goulding threatened to call off her performance, what was the local response from the Salvation Army?

Local leadership for the Salvation Army initially routed inquiries about the halftime show to national staff, said Rich, the commander for the Dallas-Fort Worth area.

He said hes convinced that there was a silver lining to Gouldings concerns.

It brings attention to how inclusive we are as an organization and serving everyone no matter who they are, what their sexual orientation is, what their station in life is. We serve without discrimination, Rich said. It's our international mission statement that we serve human needs without discrimination.

What happened behind the scenes that cleared the way for the performance to proceed as planned?

Rich said Salvation Army leadership was taken aback by Gouldings initial statement.

We jumped into action to say, Wow, we really need to respond to this and help Ellie feel good about representing this national Kettle Kickoff in support of all the people that we serve all year long, he said. Our team at national met with Ellie's team and really talked through and helped her understand our non-discrimination policies the way that we truly are have open arms for anyone who's in need regardless of their situation.

Is this idea that the Salvation Army is not LGBTQ-friendly a sentiment that you have dealt with before?

Absolutely, Rich said. The Salvation Army is a huge organization: 130 countries, thousands and thousands of officers and employees, and then millions and millions 23 million in the United States alone we serve every year.

Sometimes, he said, someone within the organization says or does something that doesnt represent the values of the Salvation Army.

Unfortunately, these things happen, he said. Then these stories take a life of their own and it's really hard to get out from under that false narrative at times.

A national statement also referred to myths that can perpetuate in a large organization. But there are specific instances of anti-LGBTQ bias among people within the Salvation Army, like the Australian officer in 2012 implying that gay people should be put to death. So how do you grapple with those instances?

I don't know the whole context of what happened and why that person said what they did, Rich said. But I do know as soon as it came out on a national basis and international basis, that statement was disavowed in terms of the way that it was portrayed.

The Australian officers statement in no way represents who we are or how we love all people and include all people who are in need, Rich said.

It's certainly not Salvation Army ethos, he said. It's not Salvation Army just the spirit of who we are. It just went counter to all of that. And so it's isolated, but it makes international news, right? Because of our brand and because we're such a huge organization, one person could say something and cast a cloud over the whole thing. Well, the way you get rid of those clouds, I think, is shine a light on what we're doing every single day in a place like Carr P. Collins here in North Texas. And that makes all the difference.

Theres also an older 2014 article about a transgender woman who received emergency shelter at the Collins center but was told she could not be part of a two-year program because she hadnt had gender-affirming surgery. How would a trans person be treated if they were to arrive at the center today looking for shelter or other services?

When someone comes to a Salvation Army shelter, Fetterman said, we provide shelter in accordance with how they self-identify."

"Whether theyre pre-op or post-op or having hormone replacement therapy or not is not a factor in how we serve and how we shelter.

Fetterman, the executive director of the center on Harry Hines Boulevard, said the organization is always evolving.

She said the notion that the Salvation Army is anti-LGBTQ can sometimes hurt the most ... those that need our help but are afraid to come and access care because theyre concerned about how theyre going to be treated and if theyre going to be accepted.

What does the Salvation Armys nondiscrimination policy entail?

The Salvation Army serves all those in need without unlawful discrimination or harassment based on age, race, color, religion, sex, national origin, marital status, disability, citizenship, sexual orientation, gender identity, gender expression, or any other characteristic in accordance with our capacity to help, according to a statement on its website.

Fetterman said Salvation Army staff has regular, ongoing training on cultural sensitivity and preventing implicit bias.

What about its hiring practices?

The same policy of nondiscrimination goes for the Salvation Armys hiring practices, Fetterman said.

What would you all point to when showing how the Salvation Army has evolved on LGBTQ issues over the years?

Rich said it took the Salvation Army a while to figure out whether to offer same-sex couples health benefits when the question first came up a few decades ago.

Now, nationwide we offer health benefits to same-sex couples, no questions asked, he said. And I think ... you dont find that a lot in faith-based organizations. But we think everyone should have access to healthcare. So why wouldnt we do that?

Fetterman described a more thoughtful approach to the needs of trans people in the Salvation Armys shelters. In 2014, the mens shelters had to be gutted for renovations, she said.

When we were piecing it back together, the design team we were working with showed us the showers, she said. They were buying for the men's bathrooms, and they showed us the shower stall doors and they were waist down. We said, No, we cant do that.

Wanting to ensure better privacy and specifically thinking about the needs of a transgender man the staff insisted on doors that covered shoulders to knees.

Its things like that that are really important so that somebody will feel safe accessing shelter here, she said.

Read more from the original source:
Salvation Army disavows anti-LGBTQ stance after close call with pop star Ellie Goulding - The Dallas Morning News

NewsReal LifeEllie Water's doctors thought she'd just torn a muscle in her leg, then she was given a 20 per cent chance of survival

Friday, 15th November 2019, 1:40 pm

As part of a new series calledLiving with cancer,iis sharing people's stories about how the disease affects their life and relationships, both practically and emotionally.

When Ellie Waters felt a lump in her buttock aged 14, she ignored it for seven months. She was too embarrassed to mention it to her mother.

And when the sporty teen collapsed during a fun run after suffering a dull ache in her leg, her GP thought she'd just torn a muscle and suggested she take six weeks rest.

But then she began losing weight, became constipated, and was struggling to sit down because of the painful lump, her mother took her back to the doctors. They suspected an abscess, but a biopsy brought devastated news: Ellie was suffering a rare cancer of the soft tissue called alveolar rhabdomyosarcoma.

Because it was aggressive and classed as stage 4, and had spread to the lymph nodes in her groin, she had to have intense chemotherapy and radiation on her pelvic area, which has robbed her of the chance to have children.

The treatment brought on the menopause at just age 15. "My prognosis was bleak. I wasn't told at the time but my parents were told I had just a 20 per cent chance of surviving beyond five years," said the now 18-year-old. "I feel lucky to be here."

Gruelling treatment

Ellie said that at 14 it never crossed her mind her symptoms would be cancer.

"I'm quite a fiercely independent person, and so when my symptoms developed I just thought I'll deal with it.

"It was terrifying when I was told it was cancer. I didn't have anyone in my family who had had it and just thought people died from it."

Her doctors explained they couldn't remove the lump without causing huge disfigurement. She said the treatment 18 months of chemotherapy and 28 radiotherapy sessions took a huge toll.

"With the chemo, I was throwing up still when I had nothing left to throw up. I couldn't eat so I had a feeding tube. I suffered with foot drop and needed a wheelchair. The fatigue was overwhelming. I was like a baby needing naps around the clock. I lost my hair.

"It was quite isolating as the rest of my friends were just getting on with normal teenage things."

Not warned about fertility effects

Ellie says that she began treatment without having been warned about the effects on her ability to have children.

"Due to the late stage of my cancer, treatment started straight away with no conversation about fertility. I always had an inkling that the treatment might make me infertile as Id heard that that was a side effect, but I wasnt told initially."

Just before her radiotherapy, it was brought up as a side-effect. "To be told that I could be infertile was a shock, as I knew that I wanted to have a family at some point."

Ellie didn't ask too many questions at that stage, until she'd finished her radiotherapy. "I asked my doctor on a scale of zero to 10 zero being completely infertile and 10 being very fertile where am I? My doctor said zero.

"Not only were my eggs damaged, but I was also told that the radiotherapy had damaged my uterus to the point that I would never be able to carry a child to full term.

"It's upsetting but you just go into survival mode. My cancer was aggressive and I just wanted to make it out alive.

"I'm ok now with not having my own biological child. I'm quite excited about adoption and would love to be able to give a child a home who hasn't got one."

Dream of being a doctor

Going through the menopause at 15 has been a struggle for Ellie. Although she had to repeat Year 10 at school while battling the symptoms, she managed to do well at her GCSEs, and is now studying A-Levels.

"I was in the classroom at school and everyone was in jumpers being winter and I was having hot flushes and fanning myself.

"I had night sweats, my bones ached and I was so fatigued. I'll be on hormone replacement therapy for the rest of my life but I think the benefits outweigh the risks."

Now Ellie has aspirations to work in medicine. "I had wanted to be a female Alan Sugar, and get ahead on business, butI want to be a doctor and I've been applying for medical schools.

"It's directly because of my experience of having cancer. I'm driven by wanting to help people and I'm fascinated by medicine.

"Having cancer has been an ordeal but beating the disease has taught me I am stronger than I ever knew."

Ellie is sharing her story as part of a campaign by Teenage Cancer Trust to raise awareness of fertility issues that young people with cancer experience. You can find out morehere.

If you'd like to be featured in the Living with Cancer series email claudia.tanner@inews.co.uk.

View post:
Living with cancer: 'My treatment brought on the menopause at 15 and left me infertile' - inews

The global hormone replacement therapy market reached ~ US$ 12,000 Mn by 2019 and is anticipated grow at a CAGR of 6.0% over the forecast period 2018-2028. In this hormone replacement therapy market study, the following years are considered to predict the market footprint:

The business intelligence study of the hormone replacement therapy market covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). In a bid to recognize the growth prospects in the hormone replacement therapy market, the market study has been geographically fragmented into important regions that are progressing faster than the overall market. Each segment of the hormone replacement therapy market has been individually analyzed on the basis of pricing, distribution, and demand prospect for the following regions:

The key players in the global hormone replacement therapy market report consist of

Request Methodology of this Report https://www.factmr.com/connectus/sample?flag=RM&rep_id=2224

Each market player encompassed in the hormone replacement therapy market study is assessed according to its market share, production footprint, current launches, agreements, ongoing R&D projects, and business tactics. In addition, the hormone replacement therapy market study scrutinizes the strengths, weaknesses, opportunities and threats (SWOT) analysis.

On the basis of dosage form, the global hormone replacement therapy market report covers the footprint, and consumption of the segments including

The global hormone replacement therapy market covers the demand trends of each disease indications which includes:

What insights readers can gather from the hormone replacement therapy market report?

The hormone replacement therapy market report answers the following queries:

Request Sample Report https://www.factmr.com/connectus/sample?flag=S&rep_id=2224

Why Choose Fact.MR?

Original post:
Hormone Replacement Therapy Market Rapid Growth with Rising Application Scope by 2028 - Daily Health Tribune

Share

Share

Share

Email

Global Compounding Pharmacies Market: Overview

Personalized medications have gained traction in recent years. This popularity is the key factor that is driving the growth of global compounding pharmacies. Currently, the trend for made from scratch is one of the factors responsible for the growth of the market. This trend is elevating the visibility of compounding pharmacies across the globe. The fact that medications are made from blending ingredients as per their strength and dosage makes them optimal for addressing issues of precise drug usage. Moreover, developing user specific drug to cater to patients need is another factor that is boosting the growth of global compounding pharmacies market in the forecast period of 2018 to 2028.

Shedding light upon crucial facets like notable developments, key drivers, and market opportunities a report by TMR Research provides in-depth analysis of global compounding pharmacies market for 2018 to 2028.

Global Compounding Pharmacies Market: Notable Developments & Competitive Analysis

Collaborations and Acquisitions are two tools that companies in global compounding pharmacies market are adopting to stand out in tough competition of the market. These strategies allow the players to accumulate necessary resources that can help the businesses to have a sustainable future in the global compounding pharmacies market. Additionally these strategies allow the two companies to leverage the technology present with one of the organizations that can help them increase the production medicines.

Some of the prominent players of global compounding pharmacies market are:

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Compounding Pharmacies Market: Key Drivers

Compounded Pain Management Drugs A Major Driving Factor

Pain management is gaining major traction these days. The growing popularity of pain management therapy is the major factor that is boosting the growth of the compounding pharmacies in the forecast period of 2018 to 2028. The drugs are FDA-approved yet come under State Pharmacies Boards supervision. For instance, a guideline for chronic pain stated by Medical Treatment Utilization Schedule does not support the use of compounds like Gabapentin and Baclofen for pain management. However, compounding pharmacies use these compounds to improve strength of the drug.

Hormone Replacement Therapeutics Drive Major Revenue

Oral medicines are driving maximum revenue for global compounding pharmacies market. These medicines account or more than 38.4% of total revenue in the forecast period of 2018 to 2028. The medicines are majorly used in hormones replacement therapies. This is because of the development of the drugs that can stimulate the production of hormones without injecting them externally. Moreover, relatively easy manufacturing of these drugs is another factor that elevates the positions of hormonal therapeutic drugs in global compound pharmacies market during the forecast period of 2018 to 2028.

Shortage of Prescription Plays a Crucial Role

The medical sector is witnessing a major shortfall for prescription drugs in recent years. This scarcity is the major factor that is fueling the growth of global compounding pharmacies market. According to FDA only 154 drugs are currently available to treat chronic pain across the globe. Compounding pharmacies can bridge this gap between demands and supply generating major revenue for the global compounding market in 2018 to 2028.

Global Compounding Pharmacies Market: Regional Analysis

The global compounding pharmacies market is expected to witness maximum potential in North America. The dominance of the region is attributed to the technological developments to boost the production of drugs and presence of various prominent players of the market.

The global Compounding Pharmacies Market is segmented on the basis of:

Get Discount on Latest Report @CLICK HERE NOW

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Original post:
Compounding Pharmacies Market Demand Drives and Growth Opportunities and Forecast to 2028 - Tech Admirers

The population of women in Duluth over 45 is estimated by the U.S. Census Bureau at 28,000.

Women most affected by menopausal symptoms are between 45 and 64. My mother, aunts, and grandmother are all of this age and all have weathered their menopausal changes, some with the aid of prescription hormone replacement therapy.

A shared experience is of a healthy, shift-working woman, 45 years old, struggling with significant night sweats and insomnia for three months. She makes an appointment with her primary-care provider, who has been seeing her regularly for health care for the last few years, since after the birth of her daughter. She previously had regular care with her OB/GYN doctor but felt too old for her follow-up routine visits. So she transitioned to a local primary-care provider. At this visit, she hoped to receive some aid for her bothersome symptoms.

I dont have the luxury to be this tired all the time from not sleeping due to these horrible night sweats, she said to her doctor. I need to be efficient at work so I can provide for my family. Is there something I can take or do?

Her primary replied, I have to refer you to an OB/GYN, because I do not have the expertise to manage patients with hormone replacement therapy, which is a treatment that can help you.

She is frustrated because she took off work for this visit and now has to make another visit in the OB/GYN office in three weeks and has an additional drive of 35 minutes. But she complies.

At her next visit, she is struck with how old she feels, surrounded in the waiting room by young expecting mothers and their buzzing children. She meets with the OB/GYN provider, who spends a brief seven minutes with her, and she leaves feeling very comfortable with a new prescription of hormone replacement therapy.

The problem is this common treatment of hormone replacement therapy, or HRT, is not routinely instructed to primary-care providers in their mandatory continuing-education requirements, particularly in low-risk women. Primary-care providers are required to have continued education as part of their licensure to practice medicine.

These providers serving female patients include medical doctors, nurse practitioners, advanced-practice registered nurses, and physician assistants. This problem leads to increased costs and referrals for low-risk patients and a loss of revenue for providers who have the capacity to manage this highly effective and safe therapy for close to half of their patient population.

As a womens-health nurse practitioner, I have heard this common story from many female patients, and it is time for the health care system to listen. All primary-care providers need regular, mandatory continuing education on hormone replacement therapy treatments. This mandatory education should include the large body of evidence that supports the safe use of HRT in menopausal women and the important risk factors when HRT is not appropriate.

HRT can be counseled, prescribed, and managed in low-risk women by primary-care providers.

Regionally, the practice of managing HRT is diverse and is very typical practice in urban settings while much less common practice in rural areas where primary-care providers are pivotal.

My primary-care colleagues continue to ask how to treat female patients who have multiple high-risk factors and who shouldnt be on HRT. My rebuttal is that their keen knowledge is correct: HRT is likely not the treatment for these female patients. A referral to an expert in womens health is highly encouraged for high-risk women. The population of high-risk women is typically amongst younger ages or is found during pregnancy or through routine surveillance in all care settings.

With mandatory continuing education for primary-care providers in managing safe hormone replacement therapy for women, their confidence in the medications and the management of these low-risk women will increase, along with provider satisfaction from patients.

Kelsey Thompson of Duluth is a womens-health nurse practitioner in Minneapolis. She received a bachelors degree in nursing from the College of St. Scholastica. She earned a masters in womens health and a doctorate in nursing from Duke University in North Carolina.

See more here:
Nurse's View Column: Health care system failing the women in our families - Duluth News Tribune